Using light therapy to treat mouth sores in blood cancer patients
Validation of the Improvement in the Management of Chemo-induced Mucositis in Hematology Through the Contribution of Photobiomodulation - The PHOTO-TREAT Study
This study is testing if light therapy can help reduce mouth sores in blood cancer patients who are undergoing chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut de cancérologie Strasbourg Europe Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06326268 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of photobiomodulation, a form of light therapy, in managing chemo-induced mucositis among patients with hematologic malignancies. The research is conducted at the Strasbourg Cancer Institute and aims to validate the benefits of this treatment in reducing the severity and incidence of mucositis, a common complication of chemotherapy. Participants will receive treatment using the CareMin650TM phototherapy system, with the goal of improving patient comfort and outcomes during their cancer treatment.
Who should consider this trial
Good fit: Ideal candidates include adult patients undergoing treatment for acute myeloblastic leukemia or those receiving allografts or autografts for aggressive lymphoma.
Not a fit: Patients who are pregnant, breastfeeding, or have allergies to polyurethanes may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the pain and complications associated with chemo-induced mucositis in blood cancer patients.
How similar studies have performed: Previous studies in pediatric hematology have shown success with low-dose laser treatment for similar conditions, indicating potential for this approach in adult patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient; * Patients: In induction of acute myeloblastic leukemia OR Allografts in first remission with myeloablative conditioning OR Autografts in the context of aggressive lymphoma; * Signature of informed consent; * Patient registered with social security. Exclusion Criteria: * Patient under guardianship or curatorship * Pregnant and breastfeeding woman * Allergy to polyurethanes
Where this trial is running
Strasbourg
- Institut de cancérologie Strasbourg Europe — Strasbourg, France (Recruiting)
Study contacts
- Principal investigator: Anne ZILLIOX, MD — Institut de cancérologie Strasbourg Europe
- Study coordinator: Claire VIT
- Email: promotion-rc@icans.eu
- Phone: (0)3 68 33 95 23
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.